Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, on June 2, 2015 announced data demonstrating the ability of its plasma-based liquid biopsy panel for solid tumors, which co-isolates and analyzes exosomal RNA (exoRNA) and cell-free DNA (cfDNA), to provide robust, highly sensitive detection of actionable mutations in plasma across multiple cancers. The company announced additional data showing that its proprietary exoRNA plus cfDNA platform also enabled plasma-based longitudinal monitoring of BRAF mutant melanoma, and demonstrated the ability to detect early disease progression multiple months prior to clinical evidence of the changes. Exosome Diagnostics is developing innovative plasma- and urine-based liquid biopsies that analyze exoRNA for biomarkers and can simultaneously isolate and analyze cfDNA to enhance detection of rare mutations. The solid tumor liquid biopsy panel and BRAF data were presented in poster sessions at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, that took place May 29 – June 2 in Chicago, Illinois. Based on these and earlier data, Exosome Diagnostics plans to commercialize its solid tumor panel liquid biopsy as a laboratory-developed test in the company’s certified CLIA laboratory in 2015. The test, which is performed on simple blood samples, and covers 26 genes and 1000 associated mutations in the most significant cancer pathways, including EGFR/MAPK and PI3K, will initially be made available to pharmaceutical companies as a clinical development tool. “These findings further validate our unique, exoRNA-based liquid biopsy approach, and the potential clinical significance of analyzing exoRNA to reveal molecular insights about cancer,” said Vince O’Neill, M.D., Chief Medical Officer of Exosome Diagnostics.Login Or Register To Read Full Story